Cabozantinib and apixaban: an hitherto unreported interaction

We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib. This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 24 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Kasey Halsey, Jing Wu, Chang Su, Ben Hsieh, Thomas Yi, Scott A. Collins, Benjamin Kimia, Paul J. Zhang, Terrance Healey, Zishu Zhang, Harrison X. Bai
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: European Journal of RadiologyAuthor(s): Lisa Loi, Ferdinand Zimmermann, Steffen Goerke, Andreas Korzowski, Jan-Eric Meissner, Katerina Deike-Hofmann, Anne Stieber, Peter Bachert, Mark Edward Ladd, Heinz-Peter Schlemmer, Sebastian Bickelhaupt, Sarah Schott, Daniel Paech
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionThe proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.Key Points• The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy.• The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response.• SLICs+MTh-based necrosis w...
Source: European Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: Pathology - Research and PracticeAuthor(s): Tania Franceschini, Elisa Capizzi, Francesco Massari, Riccardo Schiavina, Michelangelo Fiorentino, Francesca Giunchi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: May 2020Source: Journal of Comparative Pathology, Volume 177Author(s): L.M.C. Soares, A.H.B. Pereira, C.G. de Campos, L.S. Rocha, T.Á. dos Santos, M.A. Souza, P.C. Jark, C.A. Pescador
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
AbstractPatients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagul...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Neuro-Oncology, Symptom Management and Supportive Care Source Type: research
Abstract Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Conclusions: The combination of cetuximab and regorafenib was well tolerated at doses of cetuximab IV 200 mg/m2 followed by 150 mg/m2 weekly, with regorafenib 80 mg daily. Anticancer activity was observed in patients with wild type colorectal cancer.Citation Format: Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook. Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal an...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Kidney Cancer | Oral Cancer | Renal Cell Carcinoma | Thrombocytopenia | Toxicology